| mRNA |
Cytarabine |
GDSC1000 |
pan-cancer |
AAC |
0.2 |
3e-06 |
| mRNA |
PD-0325901 |
CCLE |
pan-cancer |
AAC |
0.24 |
3e-06 |
| mRNA |
PL-DI |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
4e-06 |
| mRNA |
Compound 23 citrate |
CTRPv2 |
pan-cancer |
AAC |
-0.18 |
5e-06 |
| mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
-0.15 |
5e-06 |
| mRNA |
PI-103 |
GDSC1000 |
pan-cancer |
AAC |
-0.17 |
6e-06 |
| mRNA |
Cerulenin |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
8e-06 |
| mRNA |
CI-1040 |
GDSC1000 |
pan-cancer |
AAC |
0.18 |
8e-06 |
| mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.18 |
1e-05 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
1e-05 |